News

The Lancet2d
Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial - The Lancet ...
In the last 36 months, W. Doehner received research support from Vifor (to institution), Boehringer Ingelheim (to institution) and the EU commission; consulting fees from Aimediq, Bayer, Boehringer ...